Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 10/20 | 0.51 |
| ▸ | SLC5A1 | P13866 | 7/20 | 0.51 |
| ▸ | DHFR | P00374 | 1/20 | 0.44 |
| ▸ | NQO1 | P15559 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15748708 | 0.88 | PKM (0.47) | SLC5A2SLC5A1DHFRSMN1; SMN2LMNA | |
| SCHEMBL18418928 | 0.86 | DHFR (0.46) | SLC5A2SLC5A1DHFRNQO1SMN1; SMN2 | |
| SCHEMBL18109 | 0.85 | SLC5A2 (0.40) | SLC5A2SLC5A1 | |
| SCHEMBL180996 | 0.84 | SLC5A1 (0.46) | SLC5A2SLC5A1LMNA | |
| SCHEMBL15682905 | 0.84 | SLC5A2 (0.53) | SLC5A2SLC5A1DHFRNQO1SMN1; SMN2 | |
| SCHEMBL17916 | 0.83 | SLC5A2 (0.52) | SLC5A2SLC5A1DHFRNQO1SMN1; SMN2 | |
| SCHEMBL1456830 | 0.83 | DHFR (0.43) | SLC5A2SLC5A1DHFRNQO1SMN1; SMN2 | |
| SCHEMBL38150 | 0.83 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL29386304 | 0.83 | SLC5A2 (0.53) | SLC5A2SLC5A1 | |
| SCHEMBL28191188 | 0.83 | DHFR (0.50) | DHFRNQO1SMN1; SMN2LMNAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105001213-B | C-aryl glycoside derivative, pharmaceutical composition, preparation method and application thereof | 上海迪诺医药科技有限公司 | 2020-08-28 | — | — | CN | disclosed |
| WO-2020129899-A1 | METHOD FOR PRODUCING C-ARYL HYDROXY GLYCOXIDE DERIVATIVES | 株式会社トクヤマ | 2020-06-25 | — | — | WO | disclosed |
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| US-9914724-B2 | C-aryl glycosid derivatives, pharmaceutical composition, preparation process and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2018-03-13 | — | — | US | disclosed |
| EP-2714636-B9 | FAMILY OF ARYL, HETEROARYL, O-ARYL AND O-HETEROARYL CARBASUGARS | TFCHEM (FR) | 2017-03-22 | — | — | EP | disclosed |
| EP-3133071-A1 | C-ARYL INDICAN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF | Shanghai De Novo Pharmatech Co Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| EP-3133071-A1 | C-ARYL INDICAN DERIVATIVE, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND USES THEREOF | Shanghai De Novo Pharmatech Co Ltd. (CN) | 2017-02-22 | — | — | EP | disclosed |
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SHANGHAI DE NOVO PHARMATECH CO. LTD. (CN) | 2017-02-09 | — | — | US | disclosed |
| EP-1845095-B1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO LTD (JP) | 2011-09-07 | — | — | EP | disclosed |
| CN-102149717-A | Dioxa-bicyclo [3.2.1] octane-2, 3, 4-triol derivatives | PFIZER | 2011-08-10 | — | — | CN | disclosed |
| EP-2334687-A1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | Pfizer Inc. (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-04-28 | — | — | US | disclosed |
| US-7910619-B2 | e.g. 2,3,4,6-tetra-O-benzyl-5-thio-D-glucono-1,5-lactone3,4-Dihydro-2H-pyran; inhibit the activity of sodium-dependent glucose cotransporter 2 (SGLT2) concerned with glucose reabsorption in the kidney; antidiabetic agent; diabetes-related disease, or diabetic complication | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-03-22 | — | — | US | disclosed |
| WO-2010023594-A1 | DIOXA-BICYCLO[3.2.1.]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | PFIZER INC | 2010-03-04 | — | — | US | disclosed |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| CN-101103013-A | 1-thio-D-glucitol derivatives | TAISHO PHARMACEUTICAL CO LTD (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1845095-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056618-A1 | DIOXA-BICYCLO[3.2.1]OCTANE-2,3,4-TRIOL DERIVATIVES | SLC5A2, SLC5A1, SLC2A2 | SLC5A2 1/4885SLC5A1 2/4885DHFR 2833/4885 |
| US-20110098469-A1 | 1-THIO-D-GLUCITOL DERIVATIVES | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885DHFR 835/4885 |
| US-20170037038-A1 | C- ARYL GLYCOSID DERIVATIVES, PHARMACEUTICAL COMPOSITION, PREPARATION PROCESS AND USES THEREOF | SLC5A2, SLC5A1, MGAT1 | SLC5A2 1/4885SLC5A1 2/4885DHFR 4312/4885 |
| US-20080132563-A1 | 1-Thio-D-Glucitol Derivatives | SLC5A1, SLC5A2, SLC5A11 | SLC5A2 2/4885SLC5A1 1/4885DHFR 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.